BioGaia AB: Interim report third quarter January – September 2023
THIRD QUARTER 2023 Figures in parentheses refer to the corresponding period last year, unless otherwise specified. · Net sales amounted to SEK 317.7 million (257.7), an increase of SEK 60.0 million, or 23% (excluding foreign exchange effects, 17%). · Net sales in the Paediatrics segment amounted to SEK 255.8 million (205.7), a change of 24% (excluding foreign exchange effects an increase of 18%). · Net sales in the Adult Health segment amounted to SEK 59.2 million (50.5), an increase of 17% (excluding foreign exchange effects, an increase of 11%). · Operating expenses